About Purdue Pharma

Purdue Pharma L.P. develops and provides prescription medicines that meet the evolving needs of healthcare professionals, patients, and caregivers. We were founded by physicians and we are currently led by a physician. Beyond our efforts to provide quality medications, Purdue is committed to supporting national, regional and local collaborations to drive innovations in patient care. Privately held, Purdue is pursuing a pipeline of new medications and technologies through internal research & development and strategic industry partnerships.

Our History

  • 1892

    Dr. John Purdue Gray and George Frederick Bingham start The Purdue Frederick Company on Manhattan’s Lower East Side.

    1892

  • 1952

    Drs. Raymond and Mortimer Sackler purchase The Purdue Frederick Company and move the company to Christopher Street, New York City.

    1952

  • 1955

    Senokot® Laxatives are introduced in U.S.

    1955

  • 1958

    Cerumenex drops*, the first liquid agent for removing excess earwax, introduced.

    *Product no longer available.

    1958

  • 1959

    Arthropan (choline salicylate) liquid* for the treatment of arthritis introduced.

    *Product no longer available.

    1959

  • 1962

    Company relocates to Yonkers, NY.

    1962

  • 1966

    Betadine® broad-spectrum microbicides are acquired by Purdue.

    1966

  • 1969

    Betadine® Surgical Scrub* is used to decontaminate the Apollo lunar module after Neil Armstrong’s moonwalk.

    *Betadine products are not approved for use in the disinfection of inanimate objects.
    Photo credit: Records of the U.S. Information Agency; National Archives and Records Administration.

    1969

  • 1973

    Corporate headquarters relocates to South Norwalk, CT.

    1973

  • 1976

    Manufacturing relocates to Totowa, NJ.

    1976

  • 1977

    Trilisate (choline salicylate) tablets* for the treatment of arthritis introduced.

    *Product no longer available.

    1977

  • 1983

    Corporate headquarters relocates to Norwalk, CT. The company’s renovation of a former factory building won the Urban Land Institute Award for Excellence.

    1983

  • 1984

    Uniphyl tablets* – the world’s first oral theophylline designed for once-a-day use to control asthma – introduced.

    *Product no longer available.

    1984

  • 1987

    MS Contin® (morphine sulfate extended-release tablets) CII is launched. Click here for full Prescribing Information, including Boxed Warning.

    1987

  • 1991

    Purdue Pharma L.P. is formed.

    1991

  • 1996

    OxyContin® (oxycodone HCl) extended-release tablets CII is launched. Click here for full Prescribing Information, including Boxed Warning.

    1996

  • 2000

    Purdue relocates to One Stamford Forum, a distinctive tiered office tower in Stamford, CT.

    2000

  • 2000

    Purdue Pharmaceuticals L.P., a new manufacturing facility, is dedicated in Wilson, NC.

    2000

  • 2001

    Purdue occupies new headquarters building for discovery research and non-clinical development in Cranbury, NJ.

    2001

  • 2001

    Purdue develops Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System.

    2001

  • 2002

    Purdue Products L.P. is established and acquires Colace® Stool Softeners, Peri-Colace® Tablets, and Slow-Mag® Tablets.

    2002

  • 2003

    Purdue establishes RxPATROL®, a collaborative effort between industry and law enforcement designed to collect, collate, analyze, and disseminate pharmacy theft information.

    2003

  • 2005

    Purdue licenses once-daily formulation of tramadol from Labopharm Inc. of Laval, Canada.

    2005

  • 2005

    Radio frequency ID tags and color-shifting ink integrated into OxyContin® packaging.

    2005

  • 2009

    Purdue licenses zolpidem tartrate sublingual tablets from Transcept Pharmaceuticals, Inc.

    2009

  • 2010

    Reformulation of OxyContin® (oxycodone HCl) extended-release tablets CII is launched.

    Click here for full Prescribing Information, including Boxed Warning.

    2010

  • 2011

    Butrans® (buprenorphine) Transdermal System CIII is launched. Click here for fullPrescribing Information, including Boxed Warning.

    2011

  • 2012

    Intermezzo® (zolpidem tartrate) sublingual tablet CIV is launched. Click here for full Prescribing Information, including Boxed Warning.

    2012

  • 2013

    FDA approves new labeling in Section 9.2 of Full Prescribing Information for reformulated OxyContin (oxycodone HCl) extended-release tablets CII. Click here for full Prescribing Information, including Boxed Warning.

    2013

  • 2013

    FDA approves 15 mcg/hour dosage strength of Butrans. Click here for full Prescribing Information, including Boxed Warning.

    2013

  • 2014

    Purdue Pharma L.P. Commercially Launches Recently Approved 7.5 mcg/hour Dosage Strength of Butrans® (Buprenorphine) Transdermal System CIII. Click here for full Prescribing Information, including Boxed Warning.

    2014

  • 2015

    Hysingla® ER (hydrocodone bitartrate) Extended-Release Tablets CII launched. Click here for full Prescribing Information, including Boxed Warning.

     2015

  • 2015

    Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant

    2015

  • 2015

  • 2015

    Purdue Pharma L.P. and AnaBios Corporation Initiate Program to Accelerate Development of Chronic Pain Treatment

    2015

  • 2017

  • Corporate
  • Products
  • Programs
  • Business
    Development